Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus Docetaxel in HER2-negative advanced breast cancer
NCT00393939Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of sunitinib in breast cancer, sponsored by Pfizer. Primary endpoint: Progression-Free Survival at 33 months. Started Feb 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00393939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393939.